Serine metabolism in LRRK2-G2019S mutated Parkinson’s disease

Takeaway

  • In human-derived stem cells, the LRRK2-G2019S mutation was associated with reduced cell viability and metabolic activity, but the difference was only partially explained by the mutation and the serine racemase (SRR) gene was identified as a potential genetic modifier.

Why this matters

  • The LRRK2-G2019S mutation is the most common mutation that causes autosomal dominant Parkinson’s disease (PD).

  • The SRR enzymatic product, D-serine, rescued the cell viability and metabolic deficits in LRRK2-G2019S cells, suggesting SRR could be a target for PD diagnosis and treatment.